1: Br J Nutr. 2004 Nov;92(5):757-61. 

Potential modulation of plasma ghrelin and glucagon-like peptide-1 by
anorexigenic cannabinoid compounds, SR141716A (rimonabant) and
oleoylethanolamide.

Cani PD, Montoya ML, Neyrinck AM, Delzenne NM, Lambert DM.

Unite de Pharmacocinetique, Metabolisme, Nutrition et Toxicologie, Ecole de
Pharmacie, Universite catholique de Louvain, Brussels, Belgium.

The CB1 cannabinoid receptor antagonist,
N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carbox
amide (rimonabant; SR141716A), and oleoylethanolamide (OEA) are known to reduce
food consumption, by, at least partially, a peripheral regulation of feeding.
The effects of systemic SR141716A or OEA (5 mg/kg) administrations on food
consumption in 24 h food-deprived and fed rats were investigated. In fasted
rats, SR141716A and OEA produced an inhibition in food intake measurable the
first 20 min following injection. The increase in ghrelin levels observed in the
vehicle-injected rats was abolished in animals receiving OEA and significantly
reduced with SR141716A. Neither OEA nor SR141716A modified glucagon-like
peptide-1 (7-36) amide portal levels 20 min after the administration. In fed
rats, plasma ghrelin levels of SR141716A- and OEA-treated rats were 35% lower as
compared with those of the vehicle-injected rats. These results show an
influence of cannabinoid agents on circulating ghrelin levels and suggest that
their short-term action on appetite seems to be in accordance with the control
of secretion of gastrointestinal orexigenic peptides, mainly expressed in the
upper part of the gastrointestinal tract.

PMID: 15533263 [PubMed - in process]